Valuation: Royalty Pharma plc

Market Cap 29.91B 26.79B 24.64B 22.33B 41.74B 2,840B 42.52B 294B 118B 1,494B 112B 110B 4,712B P/E 2026 *
27.3x
P/E 2027 * 19.3x
Enterprise Value 38.91B 34.85B 32.05B 29.04B 54.29B 3,694B 55.3B 382B 153B 1,943B 146B 143B 6,128B EV / Sales 2026 *
11.1x
EV / Sales 2027 * 10.2x
Free-Float
72.42%
Yield 2026 *
1.5%
Yield 2027 * 1.61%
1 day+1.90%
1 week+5.20%
Current month+15.11%
1 month+15.11%
3 months+13.83%
6 months+34.12%
Current year+73.86%
1 week 63.48
Extreme 63.485
67.7
1 month 55.13
Extreme 55.13
67.7
Current year 38.29
Extreme 38.29
67.7
1 year 36.03
Extreme 36.027
67.7
3 years 24.05
Extreme 24.05
67.7
5 years 24.05
Extreme 24.05
67.7
10 years 24.05
Extreme 24.05
67.7
Manager TitleAgeSince
Chief Executive Officer 62 01/01/1996
Director of Finance/CFO 44 01/01/2010
Chief Tech/Sci/R&D Officer - 21/09/2023
Director TitleAgeSince
Chairman 62 01/04/2020
Director/Board Member 68 11/02/2020
Director/Board Member 63 16/06/2020
Date Insider Type Main position Quantity % Market Cap. Importance
5/10/26 Sell

Executive/Senior Manager

-4,126 0.0009%
30/9/26 Free

Director

642 0.0001%
28/9/26 Sell

Executive/Senior Manager

-4,126 0.0009%
Change 5-day change 1-year change 3-year change Capi.($)
+1.90%+5.20%+81.86%+151.61% 29.91B
+3.19%+11.31%+67.86%+150.58% 1,263B
-0.73%+3.56%+44.51%+85.81% 658B
+1.41%+3.24%+29.22%+107.83% 521B
+0.42%+3.20%+54.15%+67.18% 391B
+2.18%+2.93%+73.30%+45.62% 369B
+1.12%+4.52%+35.30%+58.08% 307B
+6.96%+8.86%+11.27%+36.62% 290B
+1.15%+6.09%+59.59%+77.06% 252B
+3.06%+9.38%+44.11%+119.47% 212B
Average +1.75%+5.83%+50.12%+89.99% 429.18B
Weighted average by Cap. +1.20%+6.59%+51.10%+98.68%

Financials

2026 *2027 *
Net sales 3.51B 3.14B 2.89B 2.62B 4.89B 333B 4.98B 34.44B 13.82B 175B 13.16B 12.88B 552B 3.82B 3.43B 3.15B 2.85B 5.34B 363B 5.44B 37.57B 15.08B 191B 14.35B 14.05B 602B
Net income 1.47B 1.31B 1.21B 1.09B 2.04B 139B 2.08B 14.39B 5.78B 73.18B 5.5B 5.38B 231B 1.77B 1.59B 1.46B 1.32B 2.47B 168B 2.52B 17.41B 6.99B 88.49B 6.65B 6.51B 279B
Net Debt 8.99B 8.05B 7.41B 6.71B 12.55B 854B 12.78B 88.35B 35.47B 449B 33.75B 33.03B 1,417B 9.1B 8.15B 7.5B 6.79B 12.7B 864B 12.93B 89.39B 35.88B 454B 34.15B 33.42B 1,433B
Projected Income Statement - Annual - Royalty Pharma plc
Logo Royalty Pharma plc
Royalty Pharma plc is a buyer of biopharmaceutical royalties and a funder of innovation across the biopharmaceutical industry. It collaborates with innovators from academic institutions, research hospitals and non-profits from small and mid-cap biotechnology companies to global pharmaceutical companies. It funds innovation in the biopharmaceutical industry both directly and indirectly. Directly when it partners with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties. Indirectly when it acquires existing royalties from the original innovators. Its portfolio includes royalties on more than 35 commercial products, including Vertex's Trikafta and Alyftrek, GSK's Trelegy, Roche's Evrysdi, Johnson & Johnson's Tremfya, Biogen's Tysabri and Spinraza, Servier's Voranigo, AbbVie and Johnson & Johnson's Imbruvica, Astellas and Pfizer's Xtandi, Pfizer's Nurtec ODT, and Gilead's Trodelvy, and over 17 development-stage product candidates.
Employees
100
Date Price Change Volume
30/10/26 USD 67.18 +1.90% 4,662,170
29/10/26 USD 65.93 +1.71% 2,450,453
28/10/26 USD 64.82 -0.70% 2,414,519
27/10/26 USD 65.28 +0.80% 2,701,905
26/10/26 USD 64.76 +1.41% 4,108,089
Trader
Investor
Global
Quality
ESG MSCI
AAA
MarketScreener Ratings - Royalty Pharma plc
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
67.18USD
Average target price
65.38USD
Spread / Average Target
-2.69%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Royalty Pharma plc
  1. Stock Market
  2. Stocks
  3. RPRX Stock